- Home
- YRD vs EDIT Comparison
YRD vs EDIT Comparison
Compare YRD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YRD
- EDIT
- Stock Information
- Founded
- YRD 2012
- EDIT 2013
- Country
- YRD China
- EDIT United States
- Employees
- YRD N/A
- EDIT N/A
- Industry
- YRD Finance: Consumer Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YRD Finance
- EDIT Health Care
- Exchange
- YRD Nasdaq
- EDIT Nasdaq
- Market Cap
- YRD 532.3M
- EDIT 269.8M
- IPO Year
- YRD 2015
- EDIT 2016
- Fundamental
- Price
- YRD $5.78
- EDIT $3.96
- Analyst Decision
- YRD
- EDIT Buy
- Analyst Count
- YRD 0
- EDIT 11
- Target Price
- YRD N/A
- EDIT $4.56
- AVG Volume (30 Days)
- YRD 87.0K
- EDIT 3.4M
- Earning Date
- YRD 11-19-2025
- EDIT 11-03-2025
- Dividend Yield
- YRD 7.60%
- EDIT N/A
- EPS Growth
- YRD N/A
- EDIT N/A
- EPS
- YRD 2.07
- EDIT N/A
- Revenue
- YRD $856,794,857.00
- EDIT $38,901,000.00
- Revenue This Year
- YRD N/A
- EDIT N/A
- Revenue Next Year
- YRD N/A
- EDIT N/A
- P/E Ratio
- YRD $2.89
- EDIT N/A
- Revenue Growth
- YRD 12.42
- EDIT N/A
- 52 Week Low
- YRD $4.41
- EDIT $0.91
- 52 Week High
- YRD $8.74
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- YRD 42.47
- EDIT 61.51
- Support Level
- YRD $5.85
- EDIT $3.32
- Resistance Level
- YRD $6.79
- EDIT $4.29
- Average True Range (ATR)
- YRD 0.23
- EDIT 0.37
- MACD
- YRD -0.04
- EDIT -0.01
- Stochastic Oscillator
- YRD 1.92
- EDIT 57.78
About YRD Yiren Digital Ltd.
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.